Evidence map›Paper›PMID 39738202›Full record

ArticleScientific reports2024

Refining minimal engineered receptors for specific activation of on-target signaling molecules.

Masashi Miura, Masahiro Kawahara

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Masashi MiuraLaboratory of Cell Vaccine, Microbial Research Center for Health and Medicine (MRCHM), National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki-Shi, Osaka, 567-0085, Japan.
Masahiro KawaharaLaboratory of Cell Vaccine, Microbial Research Center for Health and Medicine (MRCHM), National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Saito-Asagi, Ibaraki-Shi, Osaka, 567-0085, Japan. m-kawahara@nibiohn.go.jp.

Funding

Japan Society for the Promotion of Science 23K21062
6 · The paper itself

Abstract

Since designer cells are attracting much attention as a new modality in gene and cell therapy, it would be advantageous to develop synthetic receptors that recognize artificial ligands and activate solely signaling molecules of interest. In this study, we refined the construction of our previously developed minimal engineered receptors (MERs) to avoid off-target activation of STAT5 while maintaining on-target activation of signaling molecules corresponding to tyrosine motifs. Among the myristoylated, cytoplasmic, and transmembrane types of MERs, the cytoplasmic type had the highest signaling efficiency, although there was off-target activation of STAT5 upon ligand stimulation. Tyrosine-to-phenylalanine ​​mutagenesis revealed that both the tyrosine motif for recruiting target signaling molecules and the tyrosine residues in the JAK-binding domain did not contribute to off-target activation of STAT5. Using alanine mutagenesis for Box1 of the JAK-binding domain of MERs, we ultimately found a Box1 mutation that slightly reduced activation of on-target signaling molecules but minimized off-target activation of STAT5. The refined MER enabled us to precisely analyze the signaling and cell fate-inducing properties of seven tyrosine motifs. Therefore, the refined MER, which realizes activation of on-target signaling molecules with high signal-to-noise ratios, will attract much attention as a tool for functionalizing designer cells and more broadly in the field of synthetic biology.

Indexed as

Signal TransductionSTAT5 Transcription FactorHEK293 CellsHumansJanus KinasesProtein EngineeringTyrosineJanus KinasesSTAT5 Transcription FactorTyrosine

Identifiers

PMID39738202
PMCPMC11685922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.